Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 6B, type II cytoskeletal (KRT6B)
- Target
- KRT6B
- Molecular classification
- Intermediate filament protein, Cytoskeletal protein, Type II cytokeratin
01
Overview
Keratin 6B, type II cytoskeletal (KRT6B) is a structural intermediate filament protein abundantly expressed in differentiated epithelial tissues including the skin, hair follicles, nails, and specific glandular epithelia. KRT6B partners with type I keratins such as KRT16 and KRT17 to form dense intermediate filament networks, providing mechanical strength and resilience against physical stress. Mutations in KRT6B are linked to pachyonychia congenita type 2, presenting as nail dystrophy, painful palmoplantar keratoderma, and increased skin fragility. Altered expression plays roles in cancer cell migration and epithelial differentiation, but KRT6B does not act as a classic therapeutic target or signaling protein. Its biological importance is largely structural and diagnostic, rather than pharmacological.
- Other names
- K6BCK6BCK-6BKRTL1cytokeratin-6BKeratin-6BType-II keratin Kb10PC2PC4keratin-like 1cytokeratin 6B
02
Biological functions
Structural support and resilience of epithelial cellsMaintenance of epithelial barrier integrityRegulation of epithelial differentiationModulation of cellular migrationInvolvement in wound healing
03
Disease associations
Congenital disorders (Pachyonychia congenita, especially type 2/PC-K6b)Cancer (expression changes in aggressive or migratory tumors)Other: nail dystrophy, painful palmoplantar keratoderma, hair follicle dysfunction
04
Safety considerations
Challenges with gene or protein replacement due to its structural role in tissuesMutations confer tissue fragility, but there are no specific safety concerns related to targeting KRT6B since it is not a direct drug target
05
Biomarkers
Expression changes may serve as a marker in some epithelial cancers and for distinguishing pachyonychia congenita subtypes
Beyond the preview
Go deeper on Keratin 6B, type II cytoskeletal (KRT6B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keratin 6B, type II cytoskeletal (KRT6B).